PharmiWeb.com - Global Pharma News & Resources
07-Apr-2023

Mammalian Transient Protein Expression Market is anticipated to exceed US$ 1581.6 million by 2033 | FMI

As per the latest market research conducted by FMI, the global Mammalian Transient Protein Expression Market is likely to record a CAGR of 8.5% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of US$ 697.2 million. By 2033, the valuation is expected to reach US$ 1,581.6 million.

The market for mammalian transient protein expression is likely to witness significant growth in terms of revenue. The mammalian cells for protein expression market are also expanding, which is a result of increased industry investment in research and development as well as advancements in technologies that enable more precise and effective protein creation.

Nevertheless, the use of mammalian cells for protein expression as therapeutic agents is being made easier by the development of new delivery systems, such as nanotechnology and drug-delivery vehicles, and is anticipated to propel the growth of the mammalian cells for protein expression market in the near future.

Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12807

The growing market for mammalian transient protein expression includes a significant portion devoted to the expression of transitory proteins in mammals. Companies use this technology to create functional proteins, polypeptides, and other molecules.

Key Takeaways:

  • The introduction of new delivery systems, such as nanotechnology and drug-delivery vehicles, is likely to be the significant driver of the market.
  • The global mammalian transient protein expression is expected to hold a valuation of US$ 697.2 million in 2023.
  • The global mammalian transient protein expression market is expected to surpass US$ 1,581.6 million by 2033.
  • The mammalian transient protein expression market is likely to record a CAGR of 8.5% from 2023 to 2033.
  • The biopharmaceutical companies segment recorded a CAGR of 9.8% from 2018 to 2022 and is expected to record a CAGR of 9.1% from 2023 to 2033.
  • The mammalian transient protein expression market in China is likely to record a CAGR of 9.0% over the forecast period.
  • The reagents and consumables segment recorded a CAGR of 10.6% from 2018 to 2022 and is expected to register a CAGR of 9.6% from 2023 to 2033.

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-12807

Competitive Landscape

The key players operating in the mammalian transient protein expression market are investing in mergers and acquisitions to gain a significant market share. The manufacturers are also investing in research and development and are introducing innovative methods to boost production capacity. Product development and market expansion are significant aspects of the mammalian transient protein expression market. As a result, market participants are likely to have a better overall revenue share in the global mammalian transient protein expression market.

Recent Developments:

  • In October 2020, Merck KgaA announced its expansion, which included the opening of a new membrane manufacturing facility in Darmstadt, Germany. Increasing the output of Millipore Express membranes was the objective.
  • Thermo Fisher Scientific introduced the GMP-produced Gibco CTS TrueCut Cas9 Protein in April 2022.

Significant Key Players are:

  • Thermofisher Scientific
  • Merck KGaA
  • Promega Corporation
  • Lonza
  • Agilent Technologies, Inc.
  • Bio-Rad
  • Qiagen
  • Takara Bio
  • HiMedia Laboratories.
  • Mirus
  • Sino Biological, Inc.

Last few days to get reports at discounted prices, the offer expires soon!
Request Discount @
https://www.futuremarketinsights.com/request-discount/rep-gb-12807

Key Market Segments Covered in Mammalian Transient Protein Expression Industry Research

By Product:

  • Instruments
  • Expression Vector
  • Reagents & Consumables
  • Cell Lines
    • Chinese Hamster Ovary Cells (CHO)
    • Human embryonic kidney 293 (HEK 293) cells
    • Others

By Application:

  • Bio-production
    • Antibody Production
    • Therapeutic protein production
  • Functional Cell-Based Assays
  • Academic Research
  • Others

By End User:

  • Contract Research Organization
  • Biopharmaceutical Companies
  • Academic & Research Institutes

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Editor Details

Last Updated: 07-Apr-2023